CCR2 and colitis: In this study, we investigated whether irbesartan, which potentially acts as a direct CCR2 antagonist, prevents colitis, intestinal fibrosis and tumourigenesis, in an azoxymethane (AOM) and dextran sodium sulphate (DSS) mouse model of colitis-associated CRC29.